Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 18;14(3):e077173.
doi: 10.1136/bmjopen-2023-077173.

Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial

Ashok Ainkaran Ganeshalingam  1   2   3 , Nicolai Gundtoft Uhrenholt  4   5 , Sidse Arnfred  6 , Peter Haulund Gæde  7 , Niels Bilenberg  5   8 , Jan Frystyk  9
Affiliations

Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial

Ashok Ainkaran Ganeshalingam et al. BMJ Open. .

Abstract

Introduction: Subjects with schizophrenia have a 2-3 fold higher mortality rate than the general population and a reduced life expectancy of 10-20 years. Approximately one-third of this excess mortality has been attributed to obesity-related type 2 diabetes (T2D) and to cardiovascular disease. Glucagon-like peptide-1 (GLP-1) analogues increase satiety and delay gastric emptying, thereby reducing food intake and weight. GLP-1 analogues also exert beneficial effects on cardiovascular outcomes in high-risk patients with T2D.Our aim is to investigate whether 30 weeks add-on treatment with the GLP-1 analogue semaglutide can reduce HbA1c sufficiently to reverse pre-diabetes and the metabolic syndrome in overweight schizophrenic patients.

Methods and analysis: We will perform a 30 week, two-armed, multicentre, superiority, double-blinded, randomised trial investigating the effect of weekly injections of semaglutide versus placebo in mental health facilities in Region of Southern Denmark and Region of Zealand, Denmark. In total, 154 adults with schizophrenia spectrum disease, aged 18-60 years treated with second generation antipsychotic treatment, HbA1c 39-47 mmol/mol and body mass index >27 kg/m2 will be randomised to injections of 1.0 mg semaglutide or placebo. The primary outcome is changes in HbA1c. Secondary outcomes encompass metabolic measures, psychotic symptoms and quality of life. Exploratory outcomes encompass insulin sensitivity, cardiovascular risk profile, medication adherence, general well-being and physical activity.

Ethics and dissemination: This study will be carried out in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. This research has obtained approval from both the Danish Medicines Agency and The Regional Committees on Health Research Ethics for Southern Denmark.

Trial registration number: NCT05193578 European Clinical Trials Database Number (EudraCT) 2020-004374-22, Regional Ethical Committee number S-20200182.

Keywords: General diabetes; Obesity; PREVENTIVE MEDICINE; Primary Prevention; Schizophrenia & psychotic disorders.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Flow chart.
See this image and copyright information in PMC

References

    1. Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ 2013;346:f2539. 10.1136/bmj.f2539 - DOI - PMC - PubMed
    1. Laursen TM, Plana-Ripoll O, Andersen PK, et al. . Cause-specific life years lost among persons diagnosed with schizophrenia: is it getting better or worse. Schizophr Res 2019;206:284–90. 10.1016/j.schres.2018.11.003 - DOI - PubMed
    1. Correll CU, Solmi M, Croatto G, et al. . Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry 2022;21:248–71. 10.1002/wps.20994 - DOI - PMC - PubMed
    1. Nordentoft M, Wahlbeck K, Hällgren J, et al. . Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One 2013;8:e55176. 10.1371/journal.pone.0055176 - DOI - PMC - PubMed
    1. Westman J, Eriksson SV, Gissler M, et al. . Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study. Epidemiol Psychiatr Sci 2018;27:519–27. 10.1017/S2045796017000166 - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data